EMLHIGH SIGNALFINANCIAL10-K

EML experienced a substantial deterioration in operating performance with operating cash flow and operating income both declining meaningfully year-over-year.

The company shows concerning operational headwinds with both profitability and cash generation weakening significantly. While management reduced capital expenditures and lowered total debt levels, the fundamental business performance deteriorated notably, which could signal competitive pressures or market challenges affecting core operations.

Comparing 2026-03-03 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

EML's financial performance weakened substantially across key operational metrics, with operating income declining to $10.7M and operating cash flow dropping to $8.9M. The company responded by reducing capital expenditures from $9.7M to $4.0M and paying down debt from $42.2M to $33.9M, while cash balances decreased to $7.4M. Despite some balance sheet deleveraging, the underlying operational deterioration combined with reduced cash reserves presents a concerning financial picture that warrants close monitoring.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-59.1%
$9.7M$4.0M

Capex reduced 59.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
-54.3%
$19.4M$8.9M

Operating cash flow fell 54.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
-47.1%
$14.0M$7.4M

Cash declined 47.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Income
P&L
-47%
$20.1M$10.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
-38.3%
$44.8M$27.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Share Buybacks
Cash Flow
+22%
$3.1M$3.7M

Share repurchases increased 22% — management returning capital, signals confidence in intrinsic value.

Total Liabilities
Balance Sheet
-19.7%
$114.6M$92.0M

Liabilities reduced 19.7% — deleveraging improves balance sheet strength and financial flexibility.

Total Debt
Balance Sheet
-19.7%
$42.2M$33.9M

Debt reduced 19.7% — deleveraging strengthens balance sheet and reduces financial risk.

R&D Expense
P&L
-16.9%
$4.9M$4.1M

R&D spending cut 16.9% — could signal cost discipline or concerning reduction in innovation investment.

Gross Profit
P&L
-15.3%
$67.3M$57.0M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-03-11
ADDED
As of February 15, 2026, 6,041,767 shares of the registrant s common stock, no par value per share, were issued and outstanding.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 19.
Management s Discussion and Analysis of Financial Condition and Results of Operations 20.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 69.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 73.
+7 more — sign up free →
REMOVED
As of February 15, 2025, 6,135,278 shares of the registrant s common stock, no par value per share, were issued and outstanding.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 19 Item 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 7A.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 69 Item 9A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 71 Item 13.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →